GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
---|
CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | FACs followed by SFA and Western Blotting | NA | 0.4 | 1 | 24709421
|
CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | FACs and SFA | NA | 0.4 | 1 | 29121598
|
CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | FACs followed by SFA | NA | 0.4 | 1 | 27780858
|
CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | FACs followed by SFA | NA | 0.4 | 1 | 34689150
|
CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | FACs | NA | 0.4 | 1 | 29861860
|
CD44 | 1681 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | FACs followewd by SFA | NA | 0.4 | 1 | 22014666
|
BMI1 | 1066 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 24709421
|
BMI1 | 1066 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | Western Blotting followed by SFA | NA | 0.28 | 0.1135 | 34689150
|
BMI1 | 1066 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | Western Blotting followed by SFA | NA | 0.28 | 0.1135 | 34689150
|
IL6R | 6019 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0021 | 34689150
|
NANOG | 20857 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | Western Blotting | NA | 0.28 | 0.5461 | 25379016
|
POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.6448 | 24709421
|
POU5F1 | 9221 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | Western Blotting | NA | 0.28 | 0.6448 | 25379016
|
SOX2 | 11195 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | Western Blotting | NA | 0.28 | 0.5695 | 25379016
|
STAT3 | 11364 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0223 | 34689150
|
STAT3 | 11364 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | Western Blotting followed by SFA | NA | 0.28 | 0.0223 | 34689150
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | ALDEFLUOR assay and SFA | NA | 0.12 | 0.684 | 29121598
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | ALDEFLUOR assay followed by SFA | NA | 0.12 | 0.684 | 24709421
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | ALDEFLUOR assay followed by SFA | NA | 0.12 | 0.684 | 34689150
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | FACs followed by SFA | NA | 0.12 | 0.684 | 27780858
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | FACs followed by SFA | NA | 0.12 | 0.684 | 34689150
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | Cisplatin | FACs | NA | 0.12 | 0.684 | 29861860
|
ALDH1A1 | 402 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | FACs followewd by SFA | NA | 0.12 | 0.684 | 22014666
|
TPBG | 12004 | LTM | Head and Neck Cancer | Squamous Cell Carcinoma | UM-SCC-22B | NA | FACs followed by SFA | NA | 0.12 | 0.0032 | 27780858
|